Search research articles
Contact Us
Filters
Showing results (121-130 of 165) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2003
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients
Manijeh Daneshmand, Doris A E Parolin, Holger W Hirte, et al.
Analytical Chemistry
|
July 29, 2021
Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker Controversy
Sahar Ibrahim, Cathy Lan, Catherine Chabot, et al.
Experimental Cell Research
|
November 12, 2013
Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells
Sahiti Chukkapalli, Mohamed Amessou, Ashok K Dilly, et al.
International Journal of Molecular Sciences
|
January 11, 2024
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy
Karen Gambaro, Maud Marques, Suzan McNamara, et al.
Investigational New Drugs
|
March 4, 2005
A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer
Mary J Mackenzie, Holger W Hirte, Goss Glenwood, et al.
Investigational New Drugs
|
January 22, 2021
Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors
Quincy Siu-Chung Chu, Nathaniel Bouganim, Caroline Fortier, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
July 29, 2017
The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience
Adriana Aguilar-Mahecha, Josiane Lafleur, Manuela Pelmus, et al.
Current Oncology (Toronto, Ont.)
|
November 26, 2025
Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis
Matthew Dankner, Laurie-Rose Dubé, Mark Sorin, et al.
Therapeutic Advances in Medical Oncology
|
April 7, 2023
A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology
Vladimir Lazar, Baolin Zhang, Shai Magidi, et al.
The Journal of Molecular Diagnostics : JMD
|
November 26, 2018
A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens
Miguel Alcaide, Matthew Cheung, Kevin Bushell, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 165) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2003
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients
Manijeh Daneshmand, Doris A E Parolin, Holger W Hirte, et al.
Analytical Chemistry
|
July 29, 2021
Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker Controversy
Sahar Ibrahim, Cathy Lan, Catherine Chabot, et al.
Experimental Cell Research
|
November 12, 2013
Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells
Sahiti Chukkapalli, Mohamed Amessou, Ashok K Dilly, et al.
International Journal of Molecular Sciences
|
January 11, 2024
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy
Karen Gambaro, Maud Marques, Suzan McNamara, et al.
Investigational New Drugs
|
March 4, 2005
A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer
Mary J Mackenzie, Holger W Hirte, Goss Glenwood, et al.
Investigational New Drugs
|
January 22, 2021
Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors
Quincy Siu-Chung Chu, Nathaniel Bouganim, Caroline Fortier, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
July 29, 2017
The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience
Adriana Aguilar-Mahecha, Josiane Lafleur, Manuela Pelmus, et al.
Current Oncology (Toronto, Ont.)
|
November 26, 2025
Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis
Matthew Dankner, Laurie-Rose Dubé, Mark Sorin, et al.
Therapeutic Advances in Medical Oncology
|
April 7, 2023
A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology
Vladimir Lazar, Baolin Zhang, Shai Magidi, et al.
The Journal of Molecular Diagnostics : JMD
|
November 26, 2018
A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens
Miguel Alcaide, Matthew Cheung, Kevin Bushell, et al.
Page
of 17